These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37167836)

  • 1. Evaluating primary and booster vaccination prioritization strategies for COVID-19 by age and high-contact employment status using data from contact surveys.
    Roubenoff E; Feehan D; Mahmud AS
    Epidemics; 2023 Jun; 43():100686. PubMed ID: 37167836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How severe would prioritization-induced bottlenecks need to be offset the benefits from prioritizing COVID-19 vaccination to those most at risk in New York City?
    Kim HY; Bershteyn A; McGillen JB; Braithwaite RS
    BMC Public Health; 2023 Jan; 23(1):174. PubMed ID: 36698103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers.
    Buckner JH; Chowell G; Springborn MR
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33811185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022).
    Willem L; Abrams S; Franco N; Coletti P; Libin PJK; Wambua J; Couvreur S; André E; Wenseleers T; Mao Z; Torneri A; Faes C; Beutels P; Hens N
    BMC Public Health; 2024 Apr; 24(1):1171. PubMed ID: 38671366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study.
    Beale S; Burns R; Braithwaite I; Byrne T; Lam Erica Fong W; Fragaszy E; Geismar C; Hoskins S; Kovar J; Navaratnam AMD; Nguyen V; Patel P; Yavlinsky A; Van Tongeren M; Aldridge RW; Hayward A;
    Vaccine; 2022 Dec; 40(52):7646-7652. PubMed ID: 36372668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
    Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
    J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022.
    Cegolon L; Negro C; Mastrangelo G; Filon FL;
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public Perspectives on COVID-19 Vaccine Prioritization.
    Persad G; Emanuel EJ; Sangenito S; Glickman A; Phillips S; Largent EA
    JAMA Netw Open; 2021 Apr; 4(4):e217943. PubMed ID: 33835172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    van Ewijk CE; Hazelhorst EI; Hahné SJM; Knol MJ
    Vaccine; 2022 Nov; 40(46):6664-6669. PubMed ID: 36216647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
    Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
    J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region.
    Liu Y; Sandmann FG; Barnard RC; Pearson CAB; ; Pastore R; Pebody R; Flasche S; Jit M
    medRxiv; 2021 Jul; ():. PubMed ID: 34282421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine.
    Ripabelli G; Sammarco ML; Rezza G; D'Amico A; De Dona R; Iafigliola M; Parente A; Samprati N; Santagata A; Adesso C; Natale A; Di Palma MA; Cannizzaro F; Dentizzi C; Stefanelli P; Tamburro M
    J Community Health; 2022 Aug; 47(4):598-603. PubMed ID: 35334031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.